• Je něco špatně v tomto záznamu ?

Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity

H. Wu, K. Yang, Z. Zhang, ED. Leisten, Z. Li, H. Xie, J. Liu, KA. Smith, Z. Novakova, C. Barinka, W. Tang,

. 2019 ; 62 (15) : 7042-7057. [pub] 20190717

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc20023749

Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90. HDAC6 is involved in multiple disease-relevant pathways. Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand. We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degradation for the antiproliferation of multiple myeloma (MM). This new class of degraders exhibited improved potency and selectivity for the degradation of HDAC6. After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023749
003      
CZ-PrNML
005      
20201214131041.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1021/acs.jmedchem.9b00516 $2 doi
035    __
$a (PubMed)31271281
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Wu, Hao
245    10
$a Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity / $c H. Wu, K. Yang, Z. Zhang, ED. Leisten, Z. Li, H. Xie, J. Liu, KA. Smith, Z. Novakova, C. Barinka, W. Tang,
520    9_
$a Histone deacetylase 6 (HDAC6) primarily catalyzes the removal of acetyl group from the side chain of acetylated lysine residues in cytoplasmic proteins such as α-tubulin and HSP90. HDAC6 is involved in multiple disease-relevant pathways. Based on the proteolysis targeting chimera strategy, we previously developed the first HDAC6 degrader by tethering a pan-HDAC inhibitor with cereblon (CRBN) E3 ubiquitin ligase ligand. We herein report our new generation of multifunctional HDAC6 degraders by tethering selective HDAC6 inhibitor Nexturastat A with CRBN ligand that can synergize with HDAC6 degradation for the antiproliferation of multiple myeloma (MM). This new class of degraders exhibited improved potency and selectivity for the degradation of HDAC6. After the optimization of the linker length and linking positions, we discovered potent HDAC6 degraders with nanomolar DC50 and promising antiproliferation activity in multiple myeloma (MM) cells.
650    _2
$a antitumorózní látky $x farmakologie $x terapeutické užití $7 D000970
650    _2
$a proliferace buněk $x účinky léků $x fyziologie $7 D049109
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a vyvíjení léků $x metody $7 D000076722
650    _2
$a HeLa buňky $7 D006367
650    _2
$a buňky Hep G2 $7 D056945
650    _2
$a histondeacetylasa 6 $x antagonisté a inhibitory $x metabolismus $7 D000073864
650    _2
$a inhibitory histondeacetylas $x farmakologie $x terapeutické užití $7 D056572
650    _2
$a lidé $7 D006801
650    _2
$a MFC-7 buňky $7 D061986
650    _2
$a mnohočetný myelom $x farmakoterapie $x enzymologie $7 D009101
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Yang, Ka
700    1_
$a Zhang, Zhongrui
700    1_
$a Leisten, Eric D
700    1_
$a Li, Ziyuan
700    1_
$a Xie, Haibo
700    1_
$a Liu, Jin
700    1_
$a Smith, Kerry A
700    1_
$a Novakova, Zora $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV , Prumyslova 595 , 252 50 Vestec , Czech Republic.
700    1_
$a Barinka, Cyril $u Institute of Biotechnology of the Czech Academy of Sciences, BIOCEV , Prumyslova 595 , 252 50 Vestec , Czech Republic.
700    1_
$a Tang, Weiping
773    0_
$w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 62, č. 15 (2019), s. 7042-7057
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31271281 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214131039 $b ABA008
999    __
$a ok $b bmc $g 1596068 $s 1114425
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 62 $c 15 $d 7042-7057 $e 20190717 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
LZP    __
$a Pubmed-20201125

Najít záznam

Citační ukazatele

    Možnosti archivace